US Bancorp DE Sells 20,844 Shares of Icon Plc $ICLR

Key Points

• US Bancorp DE significantly reduced its stake in Icon Plc by 71.8%, selling 20,844 shares in the 2nd quarter, leaving it with 8,191 shares valued at approximately $1,191,000.
• Icon Plc reported earnings per share (EPS) of $3.26, exceeding analysts' expectations, despite a 4.8% decline in quarterly revenue year-over-year.
• Analysts have mixed views on Icon, with ratings ranging from "Strong Buy" to "Hold", and a consensus price target of $210.64 per share.

US Bancorp DE reduced its stake in Icon Plc (NASDAQ:ICLR - Free Report) by 71.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,191 shares of the medical research company's stock after selling 20,844 shares during the quarter. US Bancorp DE's holdings in Icon were worth $1,191,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Transcend Capital Advisors LLC increased its stake in Icon by 7.6% in the 1st quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company's stock valued at $205,000 after buying an additional 83 shares during the last quarter. First National Bank Sioux Falls increased its stake in Icon by 5.7% in the 2nd quarter. First National Bank Sioux Falls now owns 1,580 shares of the medical research company's stock valued at $230,000 after buying an additional 85 shares during the last quarter. Hunter Perkins Capital Management LLC increased its stake in Icon by 0.4% in the 2nd quarter. Hunter Perkins Capital Management LLC now owns 22,399 shares of the medical research company's stock valued at $3,258,000 after buying an additional 97 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Icon by 22.8% in the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after buying an additional 110 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. increased its stake in Icon by 8.7% in the 1st quarter. Pinnacle Wealth Planning Services Inc. now owns 1,657 shares of the medical research company's stock valued at $290,000 after buying an additional 132 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

Icon Stock Down 1.8%

Shares of ICLR opened at $185.06 on Friday. Icon Plc has a 52 week low of $125.10 and a 52 week high of $301.45. The firm has a market cap of $14.95 billion, a P/E ratio of 19.04, a price-to-earnings-growth ratio of 2.80 and a beta of 1.23. The firm's 50-day simple moving average is $177.18 and its 200 day simple moving average is $157.39. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29.

Icon (NASDAQ:ICLR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, beating analysts' consensus estimates of $3.18 by $0.08. Icon had a net margin of 9.82% and a return on equity of 10.95%. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the prior year, the business earned $3.75 EPS. Icon's quarterly revenue was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. On average, analysts forecast that Icon Plc will post 13.38 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Rothschild Redb upgraded shares of Icon from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 3rd. Truist Financial lifted their price target on shares of Icon from $187.00 to $234.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Jefferies Financial Group lowered shares of Icon from a "buy" rating to a "hold" rating and lowered their price target for the company from $220.00 to $175.00 in a research note on Tuesday, September 9th. Rothschild & Co Redburn upgraded shares of Icon from a "neutral" rating to a "buy" rating and lifted their price target for the company from $184.00 to $236.00 in a research note on Wednesday, September 3rd. Finally, Robert W. Baird boosted their price objective on shares of Icon from $222.00 to $224.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Icon presently has a consensus rating of "Moderate Buy" and an average price target of $210.64.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.